Optase

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for use as a lubricant to prevent further irritation of the eye. It may also be utilized as a protectant against additional irritation and is effective in relieving dryness of the eye.

There are no teratogenic effects associated with this drug, and no nonteratogenic effects have been reported.

Dosage and Administration

Healthcare professionals are advised to administer one to two drops of the medication into the affected eyes as needed. It is important to ensure that the dropper does not come into contact with the eye or any other surface to maintain sterility. The frequency of administration should be determined based on the patient's condition and response to treatment.

Contraindications

There are no specific contraindications listed for this product. However, it is imperative to seek immediate medical assistance or contact a poison control center if the product is swallowed.

Warnings and Precautions

For external use only. To prevent contamination, it is imperative that the tip of the container not be touched to any surface. After each use, the bottle should be shaken downwards to eliminate any residual drops, and the cap must be securely replaced.

The solution should not be used if there is any change in color or if it becomes cloudy, as this may indicate a compromise in product integrity.

Healthcare professionals should advise patients to discontinue use and seek medical attention if they experience any of the following: eye pain, changes in vision, persistent redness or irritation of the eye, or if the condition worsens or persists beyond 72 hours.

In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a poison control center is recommended.

Side Effects

Patients using this product should be aware of several important warnings and potential adverse reactions. The solution is intended for external use only. To prevent contamination, patients are advised not to touch the tip of the container to any surface. After each use, it is recommended to shake the bottle downwards to remove any residual drops and to replace the cap immediately.

Patients should discontinue use and consult a healthcare professional if they experience any of the following: eye pain, changes in vision, persistent redness or irritation of the eye, or if their condition worsens or lasts longer than 72 hours. These symptoms may indicate serious underlying issues that require medical attention.

It is also important to note that the solution should not be used if it changes color or becomes cloudy, as this may indicate a compromise in product integrity.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Optase (glycerin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or a poison control center should be contacted without delay.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

There is currently no information available regarding the use of OPTASE glycerin solution/drops during pregnancy. As such, the safety of this medication in pregnant patients has not been established, and there are no known dosage modifications or special precautions recommended for use in this population. Healthcare professionals should consider the lack of data when prescribing this medication to women of childbearing potential and weigh the potential risks versus benefits.

Lactation

There are no specific statements regarding the use of this medication in nursing mothers or its effects on lactation. Additionally, there is no available data on the excretion of this medication in breast milk or its potential effects on breastfed infants. Healthcare professionals should consider the lack of information when advising lactating mothers about the use of this medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. In the absence of documented overdosage data, healthcare professionals are advised to exercise caution and monitor patients closely for any unusual symptoms or adverse effects that may arise following administration.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Continuous monitoring of vital signs and clinical status is essential to ensure patient safety.

Healthcare professionals should also consider consulting a poison control center or relevant toxicology resources for guidance on management strategies tailored to the specific circumstances of the overdosage event.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion. It is crucial to emphasize the importance of safety in the home environment, particularly for households with young children.

In the event that the medication is swallowed, healthcare providers should instruct patients to seek medical help or contact a poison control center immediately. Prompt action is essential to ensure the safety and well-being of the patient.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. There are no specific storage, handling, or disposal instructions provided. Therefore, standard storage practices should be followed to ensure product integrity. It is advisable to store the product in a controlled environment, away from direct sunlight and extreme temperatures, to maintain its efficacy.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Optase, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)